Results 191 to 200 of about 37,412,989 (241)

Physiologically Based Pharmacokinetic Model for Long-Circulating Inorganic Nanoparticles

open access: yesNano Letters, 2016
A physiologically based pharmacokinetic model was developed for accurately characterizing and predicting the in vivo fate of long-circulating inorganic nanoparticles (NPs).
Zhi Ping Xu, Li Li, Xiaowen Liang
exaly   +3 more sources

Pharmacokinetics and Physiologically-Based Pharmacokinetic Modeling of Nanoparticles

Journal of Nanoscience and Nanotechnology, 2010
The worldwide commerce involving nanoparticles will soon reach $1 trillion and already we have more than 600 commercial products containing nanoparticles. Because nanoparticles are invisible and little is known about their toxicities, there has been concern about health effects in humans.
Raymond S H, Yang   +3 more
openaire   +2 more sources

Physiologically Based Pharmacokinetic Modeling of Nanoparticles

ACS Nano, 2010
Rapid expansion of nanoparticle research demands new technologies that will enable better interpretation of experimental data and assistance in the rational design of future nanoparticles. The use of physiologically based pharmacokinetic (PBPK) models may serve as powerful tools to meet these needs.
Li, Mingguang   +3 more
openaire   +3 more sources

Physiologically-based pharmacokinetic simulation modelling

Advanced Drug Delivery Reviews, 2002
Drug selection is now widely viewed as an important and relatively new, yet largely unsolved, bottleneck in the drug discovery and development process. In order to achieve an efficient selection process, high quality, rapid, predictive and correlative ADME models are required in order for them to be confidently used to support critical financial ...
George M, Grass, Patrick J, Sinko
openaire   +2 more sources

Physiologically Based Pharmacokinetic Modeling of Arsenic in the Mouse

Journal of Toxicology and Environmental Health, Part A, 2004
A remarkable feature of the carcinogenicity of inorganic arsenic is that while human exposures to high concentrations of inorganic arsenic in drinking water are associated with increases in skin, lung, and bladder cancer, inorganic arsenic has not typically caused tumors in standard laboratory animal test protocols.
Gentry P. Robinan,   +5 more
openaire   +3 more sources

Whole-Body Physiologically Based Pharmacokinetic Models

Expert Opinion on Drug Metabolism and Toxicology, 2007
This review summarizes the most recent developments in and applications of physiologically based pharmacokinetic (PBPK) modeling methodology originating from both the pharmaceutical and environmental toxicology areas. It focuses on works published in the last 5 years, although older seminal papers have also been referenced.
Ivan Nestorov
exaly   +3 more sources

Physiologically Based Pharmacokinetic/Toxicokinetic Modeling

2012
Physiologically based pharmacokinetic (PBPK) models differ from conventional compartmental pharmacokinetic models in that they are based to a large extent on the actual physiology of the organism. The application of pharmacokinetics to toxicology or risk assessment requires that the toxic effects in a particular tissue are related in some way to the ...
Jerry L, Campbell   +4 more
openaire   +2 more sources

A Computer-Aided Framework for Development, Identification and Management of Physiologically-Based Pharmacokinetic Models

open access: yesComputers and Chemical Engineering, 2014
The objective of this work is the development of a generic computer-aided modelling framework to support the development of physiologically-based pharmacokinetic models thereby increasing the efficiency and quality of the modelling process. In particular,
Andreas A Linninger   +2 more
exaly   +2 more sources

Physiologically based pharmacokinetic model for topotecan in mice

Journal of Pharmacokinetics and Pharmacodynamics, 2010
Topotecan is a chemotherapeutic agent of choice for the second-line treatment of recurrent ovarian cancer. In this article, we have developed a physiologically based pharmacokinetic model to characterize and predict topotecan concentrations in mouse plasma and tissues. Single intravenous (IV) doses (5, 10 and 30 mg/kg) of topotecan were administered to
Dhaval K, Shah, Joseph P, Balthasar
openaire   +2 more sources

Home - About - Disclaimer - Privacy